Skye Bioscience Inc (SKYE)

[cjarmstrong]

Generally true, though NB1222 will still be expensive even using the 505b2 pathway. $20mm won't go that far, and there are also g&a/research costs. The earlier they license the less it will cost Nemus, the tradeoff is a lower royalty. My concerns are efficacy and marketability. We know Elsohly developed a prodrug suppository years ago that was never successfully licensed. That patent expired, and we still don't know the pharmacokinetics of the THC-VHS prodrug, it may or may not be better. Elsohly mentioned that the transmucosal patch he developed (to treat glaucoma as well as cinv) initially used the suppository prodrug, but the absorption was too slow so it had to be reformulated. Will the transmucosal patch use THC-VHS? If so, wouldn't the absorption as a suppository be too quick? There are questions Nemus needs to address.

NB1222 won't add value if they can't find a partner, which is why dilution is important to consider.